Saturday, March 04, 2006


Hepatitis C Combination Therapy - SCH 503034 Jumps on the Fast Track


SCH 503034 Jumps on the Fast Track
Schering-Plough's oral HCV protease inhibitor, SCH 503034, is in phase II trials, and may make for a better combination with Peg-intron. Check-in with us regularly, as we will be keeping close tabs on this development....

VX-950 To Get Fast Tracked
As you may recall we've been saying VX-950 is the revolutionary new therapy to watch for HCV. Now it looks like the FDA agrees this treatment is quite promising and deserving of faster approval than a lesser worthy approach. Another...

A Breakthrough Discovery for Hepatitis C
The state of Florida has recently produced a study illuminating the replication and mutation of the Hepatitis C virus. This kind of progress represents a giant leap forward in tracking this persistent virus, which likely means more accurate and efficient...